Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 102.64%.

  • Rhythm Pharmaceuticals' EBITDA Margin rose 293400.0% to 102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 106.81%, marking a year-over-year increase of 1291400.0%. This contributed to the annual value of 204.04% for FY2024, which is 340700.0% up from last year.
  • Rhythm Pharmaceuticals' EBITDA Margin amounted to 102.64% in Q3 2025, which was up 293400.0% from 93.39% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year EBITDA Margin high stood at 93.39% for Q2 2025, and its period low was 98280.0% during Q1 2021.
  • Over the past 5 years, Rhythm Pharmaceuticals' median EBITDA Margin value was 458.03% (recorded in 2023), while the average stood at 6730.04%.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' EBITDA Margin skyrocketed by 947625800bps in 2022 and then plummeted by -806800bps in 2024.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' EBITDA Margin stood at 2806.22% in 2021, then surged by 83bps to 478.99% in 2022, then surged by 64bps to 170.28% in 2023, then surged by 42bps to 98.63% in 2024, then decreased by -4bps to 102.64% in 2025.
  • Its last three reported values are 102.64% in Q3 2025, 93.39% for Q2 2025, and 143.73% during Q1 2025.